Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064363 · ClinicalTrials.gov registry record · Phase 2
Talampanel in Treating Patients With Recurrent High-Grade Glioma
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064363: Completed Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00064363 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064363, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.
Interventions
- DRUG talampanel
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00064363 record still lists
NCT00064363 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which talampanel is the first listed.
NCT00064363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00064363 about?
NCT00064363 is a clinical study titled "Talampanel in Treating Patients With Recurrent High-Grade Glioma". RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.
What is the current status of trial NCT00064363?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00064363?
The interventions under investigation include: talampanel (DRUG).
Who is sponsoring clinical trial NCT00064363?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia